Cargando…
Usefulness of on‐site cytology of liver tumor biopsy in specimen sampling for cancer genomic profiling test
AIM: Appropriate sample selection with a tumor fraction ≥20% without necrosis contamination is required for successful cancer genomic profiling (CGP). Rapid on‐site evaluation (ROSE) is performed to assess adequate sampling. METHOD: This retrospective study included 54 patients who underwent CGP usi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134269/ https://www.ncbi.nlm.nih.gov/pubmed/36629136 http://dx.doi.org/10.1002/cam4.5563 |
_version_ | 1785031725077757952 |
---|---|
author | Nakabori, Tasuku Abe, Yutaro Higashi, Sena Mukai, Kaori Yoshioka, Risa Morimoto, Yuki Koyanagi, Yuki Tanada, Satoshi Nagata, Shigenori Honma, Keiichiro Ohkawa, Kazuyoshi |
author_facet | Nakabori, Tasuku Abe, Yutaro Higashi, Sena Mukai, Kaori Yoshioka, Risa Morimoto, Yuki Koyanagi, Yuki Tanada, Satoshi Nagata, Shigenori Honma, Keiichiro Ohkawa, Kazuyoshi |
author_sort | Nakabori, Tasuku |
collection | PubMed |
description | AIM: Appropriate sample selection with a tumor fraction ≥20% without necrosis contamination is required for successful cancer genomic profiling (CGP). Rapid on‐site evaluation (ROSE) is performed to assess adequate sampling. METHOD: This retrospective study included 54 patients who underwent CGP using liver tumor biopsy specimen with ROSE. RESULT: The sampling success rate (98.1%) was higher than the previously reported 77.5%–88.9%. ROSE was performed once in 51 patients and twice in three patients; for those undergoing ROSE twice, the first ROSE was negative for malignancy, or showed few tumor cells with necrotic cell contamination, while the second ROSE obtained from another location showed abundant malignant cells. In these patients, the CGP was successful using the second specimen, though the first sample did not meet the required criteria for CGP test. CONCLUSION: Performing ROSE during liver tumor biopsy may be useful for CGP test sampling because ROSE prevents sampling errors and contributes to adequate sampling. |
format | Online Article Text |
id | pubmed-10134269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101342692023-04-28 Usefulness of on‐site cytology of liver tumor biopsy in specimen sampling for cancer genomic profiling test Nakabori, Tasuku Abe, Yutaro Higashi, Sena Mukai, Kaori Yoshioka, Risa Morimoto, Yuki Koyanagi, Yuki Tanada, Satoshi Nagata, Shigenori Honma, Keiichiro Ohkawa, Kazuyoshi Cancer Med BRIEF COMMUNICATION AIM: Appropriate sample selection with a tumor fraction ≥20% without necrosis contamination is required for successful cancer genomic profiling (CGP). Rapid on‐site evaluation (ROSE) is performed to assess adequate sampling. METHOD: This retrospective study included 54 patients who underwent CGP using liver tumor biopsy specimen with ROSE. RESULT: The sampling success rate (98.1%) was higher than the previously reported 77.5%–88.9%. ROSE was performed once in 51 patients and twice in three patients; for those undergoing ROSE twice, the first ROSE was negative for malignancy, or showed few tumor cells with necrotic cell contamination, while the second ROSE obtained from another location showed abundant malignant cells. In these patients, the CGP was successful using the second specimen, though the first sample did not meet the required criteria for CGP test. CONCLUSION: Performing ROSE during liver tumor biopsy may be useful for CGP test sampling because ROSE prevents sampling errors and contributes to adequate sampling. John Wiley and Sons Inc. 2023-01-11 /pmc/articles/PMC10134269/ /pubmed/36629136 http://dx.doi.org/10.1002/cam4.5563 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | BRIEF COMMUNICATION Nakabori, Tasuku Abe, Yutaro Higashi, Sena Mukai, Kaori Yoshioka, Risa Morimoto, Yuki Koyanagi, Yuki Tanada, Satoshi Nagata, Shigenori Honma, Keiichiro Ohkawa, Kazuyoshi Usefulness of on‐site cytology of liver tumor biopsy in specimen sampling for cancer genomic profiling test |
title | Usefulness of on‐site cytology of liver tumor biopsy in specimen sampling for cancer genomic profiling test |
title_full | Usefulness of on‐site cytology of liver tumor biopsy in specimen sampling for cancer genomic profiling test |
title_fullStr | Usefulness of on‐site cytology of liver tumor biopsy in specimen sampling for cancer genomic profiling test |
title_full_unstemmed | Usefulness of on‐site cytology of liver tumor biopsy in specimen sampling for cancer genomic profiling test |
title_short | Usefulness of on‐site cytology of liver tumor biopsy in specimen sampling for cancer genomic profiling test |
title_sort | usefulness of on‐site cytology of liver tumor biopsy in specimen sampling for cancer genomic profiling test |
topic | BRIEF COMMUNICATION |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134269/ https://www.ncbi.nlm.nih.gov/pubmed/36629136 http://dx.doi.org/10.1002/cam4.5563 |
work_keys_str_mv | AT nakaboritasuku usefulnessofonsitecytologyoflivertumorbiopsyinspecimensamplingforcancergenomicprofilingtest AT abeyutaro usefulnessofonsitecytologyoflivertumorbiopsyinspecimensamplingforcancergenomicprofilingtest AT higashisena usefulnessofonsitecytologyoflivertumorbiopsyinspecimensamplingforcancergenomicprofilingtest AT mukaikaori usefulnessofonsitecytologyoflivertumorbiopsyinspecimensamplingforcancergenomicprofilingtest AT yoshiokarisa usefulnessofonsitecytologyoflivertumorbiopsyinspecimensamplingforcancergenomicprofilingtest AT morimotoyuki usefulnessofonsitecytologyoflivertumorbiopsyinspecimensamplingforcancergenomicprofilingtest AT koyanagiyuki usefulnessofonsitecytologyoflivertumorbiopsyinspecimensamplingforcancergenomicprofilingtest AT tanadasatoshi usefulnessofonsitecytologyoflivertumorbiopsyinspecimensamplingforcancergenomicprofilingtest AT nagatashigenori usefulnessofonsitecytologyoflivertumorbiopsyinspecimensamplingforcancergenomicprofilingtest AT honmakeiichiro usefulnessofonsitecytologyoflivertumorbiopsyinspecimensamplingforcancergenomicprofilingtest AT ohkawakazuyoshi usefulnessofonsitecytologyoflivertumorbiopsyinspecimensamplingforcancergenomicprofilingtest |